Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | BLM | P54132 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.35 |
| ▸ | PLAU | P00749 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14736532 | 0.84 | EIF4EBP1 (0.36) | L3MBTL1HSD17B10ALDH1A1KDM4EKMT2A | |
| SCHEMBL28825372 | 0.82 | KDM4E (0.41) | L3MBTL1HSD17B10ALDH1A1KDM4EKMT2A | |
| SCHEMBL14736130 | 0.80 | ALDH1A1 (0.36) | L3MBTL1HSD17B10ALDH1A1KDM4EKMT2A | |
| SCHEMBL14754042 | 0.80 | ALDH1A1 (0.38) | L3MBTL1HSD17B10ALDH1A1KDM4EKMT2A | |
| SCHEMBL14742430 | 0.79 | ALDH1A1 (0.36) | L3MBTL1HSD17B10ALDH1A1KDM4EKMT2A | |
| SCHEMBL19156274 | 0.79 | CYP3A4 (0.40) | L3MBTL1HSD17B10ALDH1A1KDM4EKMT2A | |
| SCHEMBL14736017 | 0.79 | ALDH1A1 (0.37) | L3MBTL1HSD17B10ALDH1A1KDM4EKMT2A | |
| SCHEMBL9929200 | 0.78 | TSHR (0.39) | HSD17B10ALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL9928928 | 0.78 | CYP3A4 (0.39) | HSD17B10ALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL14742195 | 0.78 | ALDH1A1 (0.36) | L3MBTL1HSD17B10ALDH1A1KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325550-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORP (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250289823-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS | INCYTE CORPORATION | 2025-09-18 | — | — | US | disclosed |
| EP-3888657-B1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE HOLDINGS CORP (US) | 2025-03-19 | — | — | EP | disclosed |
| US-12201636-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE CORPORATION (US) | 2025-01-21 | — | — | US | disclosed |
| US-12152033-B2 | Use of pyrazolopyrimidine derivatives for the treatment of PI3K-δ related disorders | INCYTE CORPORATION (US) | 2024-11-26 | — | — | US | disclosed |
| US-20240216377-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2024-07-04 | — | — | US | disclosed |
| US-11819505-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE CORPORATION (US) | 2023-11-21 | — | — | US | disclosed |
| EP-4233869-A2 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K RELATED DISORDERS | Incyte Holdings Corporation (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230121440-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE HOLDINGS CORPORATION | 2023-04-20 | — | — | US | disclosed |
| EP-3632442-B1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K RELATED DISORDERS | INCYTE HOLDINGS CORP (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20160022685-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2016-01-28 | — | — | US | disclosed |
| US-20160024117-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2016-01-28 | — | — | US | disclosed |
| EP-2961410-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K RELATED DISORDERS | Incyte Holdings Corporation (US) | 2016-01-06 | — | — | EP | disclosed |
| US-9199982-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2015-12-01 | — | — | US | disclosed |
| WO-2014134426-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kδ RELATED DISORDERS | INCYTE CORPORATION (US) | 2014-09-04 | — | — | WO | disclosed |
| US-20140249132-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS | INCYTE CORPORATION (US) | 2014-09-04 | — | — | US | disclosed |
| CN-104024253-A | Heterocyclic amines as PI3K inhibitors | INCYTE CORP | 2014-09-03 | — | — | CN | disclosed |
| EP-2751109-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | Incyte Corporation (US) | 2014-07-09 | — | — | EP | disclosed |
| WO-2013033569-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20130059835-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249132-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS | PIK3CD, PIK3CA, PIK3CB | L3MBTL1 4195/4885HSD17B10 1032/4885ALDH1A1 2442/4885 |
| US-20230121440-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | L3MBTL1 4477/4885HSD17B10 2074/4885ALDH1A1 3232/4885 |
| US-20250325550-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | L3MBTL1 4477/4885HSD17B10 2074/4885ALDH1A1 3232/4885 |
| US-20240216377-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | L3MBTL1 4477/4885HSD17B10 2074/4885ALDH1A1 3232/4885 |
| US-20160024117-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | L3MBTL1 4477/4885HSD17B10 2074/4885ALDH1A1 3232/4885 |
| US-12152033-B2 | Use of pyrazolopyrimidine derivatives for the treatment of PI3K-δ related disorders | PIK3CD, PIK3CA, PIK3R5 | L3MBTL1 4194/4885HSD17B10 946/4885ALDH1A1 2698/4885 |
| US-11819505-B2 | Heterocyclylamines as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | L3MBTL1 4477/4885HSD17B10 2074/4885ALDH1A1 3232/4885 |
| US-20250289823-A1 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS | PIK3CD, PIK3CA, PIK3CB | L3MBTL1 4195/4885HSD17B10 1032/4885ALDH1A1 2442/4885 |
| US-20160022685-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | L3MBTL1 4477/4885HSD17B10 2074/4885ALDH1A1 3232/4885 |
| US-12201636-B2 | Heterocyclylamines as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | L3MBTL1 4477/4885HSD17B10 2074/4885ALDH1A1 3232/4885 |
| US-20130059835-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | L3MBTL1 4477/4885HSD17B10 2074/4885ALDH1A1 3232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.